374 views0 min read
Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study
Vancouver --News Direct-- Algernon Pharmaceuticals Inc.Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to provide an update on subsidiary Algernon NeuroScience successfully completing the highest planned single dose of its escalating Phase 1 clinical study of an intravenous formulation of AP-188 or DMT.... Read More...